Abstracts: Merck's profit jumps 12% on 24% sales increase. AstraZeneca says it expects to meet annual forecast. Bioglan's wrangling may be tied to deal

Faqs.org homepage :: Abstracts index :: Business, international

Merck's profit jumps 12% on 24% sales increase

Article Abstract:

Merck & Co. posted an improvement of 12% in net income for the second-quarter of 1999. The company's income were what analysts had expected. Merck benefited from strong osteoporosis, high-blood pressure, and arthritis drug sales. The company reported $1.48 billion (1.41 billin euros) in net income for the quarter. Merck's sales also improved 24% to $8.02 billion.

Comment:

Posts improvement of 12% in net income for second-quarter of 1999

author: Langreth, Robert

Publisher: Dow Jones Publishing Co. (Europe)
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 1999

United States, Merck & Company Inc.

User Contributions:

Comment about this article or add new information about this topic:

AstraZeneca says it expects to meet annual forecast

Article Abstract:

AstraZeneca PLC predicted that it will meet its yearly targets for the 2001 year. The company has been performing well during the 2001 year as of the month of December.

author: Rodgers, Susannah

Publisher: Dow Jones Publishing Co. (Europe)
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2001

Drugs & Pharmaceuticals, Pharmaceutical and Medicine Manufacturing, Drugs, Forecasts and trends, AstraZeneca PLC, AZN

User Contributions:

Comment about this article or add new information about this topic:

Bioglan's wrangling may be tied to deal

Article Abstract:

Bioglan Pharma PLC is due to post its first-half results, but has experienced difficulty lately. The pharmaceutical firm's shares fell nearly 30% in a day last month.

author: Rodgers, Susannah

Publisher: Dow Jones Publishing Co. (Europe)
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2001

Pharmaceutical preparations, Bioglan Pharma PLC

User Contributions:

Comment about this article or add new information about this topic:

subjects list: Pharmaceutical industry, Drugs, Finance, Abstract, United Kingdom

similar abstracts:

Abstracts: Aventis posts 31% increase in net, raises its targets for full year. Sanofi's net rises 54% on growth of core businesses

Abstracts: Nestle's momentum in second half is expected to lift full-year results. Emerging markets enable Nestle to lift earnings 13%

Abstracts: Tomkins says pretax profit rose 16% for year. Allders expects earnings to fall short of estimates. Iceland says sales continue to fall

Abstracts: First live ATN flight trials in Australia. Northrop buys Litton Denro

Abstracts: Austria: Genetic research for cure of muscle disease. Austria: Prevalence of osteoporosis. AUSTRIA: ORTHOPAEDIC DISEASES

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.